Fractyl Health获准在荷兰启动Rjva-001首次人体试验:首个进入2型糖尿病临床开发阶段的基因疗法候选药物

美股速递
May 11

Fractyl Health已获得授权,将在荷兰启动其候选药物Rjva-001的首次人体临床试验。这标志着该药物成为全球首个进入针对2型糖尿病临床开发阶段的基因疗法候选产品。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10